Concepts (99)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Esophageal Neoplasms | 3 | 2022 | 393 | 0.780 |
Why?
|
| Biomimetics | 1 | 2021 | 18 | 0.720 |
Why?
|
| Lung Neoplasms | 6 | 2025 | 1788 | 0.710 |
Why?
|
| Cisplatin | 1 | 2021 | 287 | 0.640 |
Why?
|
| Lung Transplantation | 1 | 2022 | 335 | 0.580 |
Why?
|
| Mesothelioma | 3 | 2024 | 94 | 0.560 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2021 | 616 | 0.550 |
Why?
|
| Peptide Fragments | 1 | 2021 | 833 | 0.530 |
Why?
|
| Granulomatous Disease, Chronic | 1 | 2016 | 69 | 0.500 |
Why?
|
| Thoracic Surgical Procedures | 1 | 2016 | 109 | 0.450 |
Why?
|
| Neoplasm Staging | 5 | 2025 | 1385 | 0.430 |
Why?
|
| Metastasectomy | 1 | 2013 | 12 | 0.430 |
Why?
|
| Adenocarcinoma | 3 | 2022 | 1070 | 0.420 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2021 | 2120 | 0.410 |
Why?
|
| Pleural Neoplasms | 2 | 2024 | 82 | 0.400 |
Why?
|
| Biomarkers, Tumor | 1 | 2021 | 1718 | 0.390 |
Why?
|
| Second-Look Surgery | 1 | 2010 | 4 | 0.340 |
Why?
|
| Chemotherapy, Cancer, Regional Perfusion | 1 | 2010 | 13 | 0.340 |
Why?
|
| Hyperthermia, Induced | 1 | 2010 | 59 | 0.330 |
Why?
|
| Peritoneal Neoplasms | 1 | 2010 | 55 | 0.320 |
Why?
|
| Laparotomy | 1 | 2010 | 142 | 0.310 |
Why?
|
| Watchful Waiting | 1 | 2024 | 78 | 0.220 |
Why?
|
| Colorectal Neoplasms | 1 | 2010 | 648 | 0.210 |
Why?
|
| Pneumonectomy | 1 | 2025 | 148 | 0.210 |
Why?
|
| Thoracic Surgery | 1 | 2025 | 162 | 0.200 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2010 | 1353 | 0.200 |
Why?
|
| Myeloid Cell Leukemia Sequence 1 Protein | 1 | 2021 | 18 | 0.180 |
Why?
|
| bcl-2-Associated X Protein | 1 | 2021 | 73 | 0.180 |
Why?
|
| Drug Synergism | 1 | 2021 | 239 | 0.170 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2025 | 377 | 0.170 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2021 | 183 | 0.170 |
Why?
|
| Societies, Medical | 1 | 2025 | 777 | 0.170 |
Why?
|
| Melanoma | 2 | 2022 | 974 | 0.160 |
Why?
|
| Tumor Cells, Cultured | 1 | 2021 | 1102 | 0.160 |
Why?
|
| Treatment Outcome | 4 | 2022 | 13011 | 0.140 |
Why?
|
| NADPH Oxidase 2 | 1 | 2016 | 41 | 0.130 |
Why?
|
| Humans | 13 | 2025 | 133950 | 0.110 |
Why?
|
| Skin Neoplasms | 1 | 2022 | 907 | 0.110 |
Why?
|
| Apoptosis | 1 | 2021 | 1929 | 0.110 |
Why?
|
| Cell Proliferation | 1 | 2021 | 2548 | 0.110 |
Why?
|
| Disease Management | 1 | 2016 | 561 | 0.100 |
Why?
|
| Antineoplastic Agents | 1 | 2021 | 1850 | 0.090 |
Why?
|
| Prospective Studies | 3 | 2024 | 6662 | 0.090 |
Why?
|
| Comorbidity | 1 | 2016 | 1617 | 0.090 |
Why?
|
| Organoplatinum Compounds | 1 | 2010 | 34 | 0.080 |
Why?
|
| Leucovorin | 1 | 2010 | 54 | 0.080 |
Why?
|
| Sample Size | 1 | 2010 | 88 | 0.080 |
Why?
|
| Fluorouracil | 1 | 2010 | 141 | 0.080 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2010 | 401 | 0.080 |
Why?
|
| Disease-Free Survival | 1 | 2010 | 971 | 0.070 |
Why?
|
| Time Factors | 2 | 2024 | 6587 | 0.070 |
Why?
|
| Biomarkers | 1 | 2016 | 3424 | 0.060 |
Why?
|
| Antigens, Neoplasm | 1 | 2009 | 407 | 0.060 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2009 | 503 | 0.060 |
Why?
|
| Genetic Therapy | 1 | 2009 | 733 | 0.060 |
Why?
|
| Male | 5 | 2024 | 65909 | 0.050 |
Why?
|
| Retrospective Studies | 2 | 2022 | 17496 | 0.050 |
Why?
|
| Mutation | 1 | 2016 | 6292 | 0.050 |
Why?
|
| Female | 5 | 2024 | 71696 | 0.050 |
Why?
|
| Ubiquitin Thiolesterase | 1 | 2022 | 65 | 0.050 |
Why?
|
| Cohort Studies | 2 | 2022 | 5185 | 0.050 |
Why?
|
| Aged | 3 | 2024 | 21740 | 0.050 |
Why?
|
| Bayes Theorem | 1 | 2022 | 315 | 0.040 |
Why?
|
| Infant | 1 | 2016 | 13176 | 0.040 |
Why?
|
| Risk Assessment | 1 | 2010 | 3700 | 0.040 |
Why?
|
| Child, Preschool | 1 | 2016 | 14820 | 0.040 |
Why?
|
| Neoadjuvant Therapy | 1 | 2022 | 404 | 0.040 |
Why?
|
| Germ-Line Mutation | 1 | 2022 | 368 | 0.040 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2022 | 509 | 0.040 |
Why?
|
| Databases, Factual | 1 | 2024 | 1242 | 0.040 |
Why?
|
| Registries | 1 | 2024 | 1569 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2021 | 1314 | 0.030 |
Why?
|
| Survival Rate | 1 | 2022 | 2210 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2024 | 2196 | 0.030 |
Why?
|
| Middle Aged | 3 | 2024 | 29411 | 0.030 |
Why?
|
| Child | 1 | 2016 | 25766 | 0.030 |
Why?
|
| Risk Factors | 1 | 2010 | 11103 | 0.030 |
Why?
|
| Prognosis | 1 | 2024 | 5080 | 0.030 |
Why?
|
| Practice Guidelines as Topic | 1 | 2021 | 1335 | 0.030 |
Why?
|
| Aged, 80 and over | 1 | 2024 | 7213 | 0.020 |
Why?
|
| Quality of Life | 1 | 2022 | 2143 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2022 | 3478 | 0.020 |
Why?
|
| Young Adult | 1 | 2024 | 9888 | 0.020 |
Why?
|
| T-Cell Antigen Receptor Specificity | 1 | 2009 | 57 | 0.020 |
Why?
|
| Melanocytes | 1 | 2009 | 50 | 0.020 |
Why?
|
| Uveitis | 1 | 2009 | 38 | 0.020 |
Why?
|
| Lymphocyte Transfusion | 1 | 2009 | 58 | 0.020 |
Why?
|
| Transplantation, Autologous | 1 | 2009 | 286 | 0.020 |
Why?
|
| Autoantigens | 1 | 2009 | 118 | 0.020 |
Why?
|
| Transduction, Genetic | 1 | 2009 | 296 | 0.020 |
Why?
|
| Adoptive Transfer | 1 | 2009 | 241 | 0.020 |
Why?
|
| Lymphocytes | 1 | 2009 | 440 | 0.020 |
Why?
|
| Adult | 2 | 2024 | 31958 | 0.020 |
Why?
|
| Hearing Loss | 1 | 2009 | 214 | 0.020 |
Why?
|
| Adolescent | 1 | 2024 | 20544 | 0.010 |
Why?
|
| Genetic Vectors | 1 | 2009 | 970 | 0.010 |
Why?
|
| Mice, Transgenic | 1 | 2009 | 2526 | 0.010 |
Why?
|
| Mice | 1 | 2009 | 18911 | 0.010 |
Why?
|
| Animals | 1 | 2009 | 36387 | 0.000 |
Why?
|